Clinical trials for Kidney cancer

114 currently recruiting clinical trials
Phase 2 Kidney cancer #NCT05865730 #2024-516711-24-00
Clear cell carcinoma Locally Advanced Metastatic
2 recruiting sites
EverImmune
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05503797 #2024-513578-23-00
Locally Advanced Metastatic BRAF 1 2 3 or more
KRAS G12C KRAS non G12C NRAS HRAS Systemic Treatment-Naive
7 recruiting sites
Fore Biotherapeutics
Phase 2 Kidney cancer #NCT05096390 #2024-513986-38-00
Papillary carcinoma Locally Advanced Metastatic None Systemic Treatment-Naive Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2 Kidney cancer #NCT04299646
Clear cell carcinoma Metastatic 1 2 0 1 or 2 Systemic Treatment-Naive Immunotherapy Targeted therapy
8 recruiting sites
Centre François Baclesse
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer #NCT05384626 #2024-514266-39-00
Locally Advanced Metastatic Metastatic Castration-resistant ALK 1 2 3 or more
AKT ATM BRAF BRCA 1/2 CDK12 CHEK 1/2 ESR FGFR HER2 HOXB13 KRAS G12C KRAS non G12C MET MSI/dMMR NRAS NTRK-1/2/3 PALB2 PIK3CA PTEN RET Systemic Treatment-Naive
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT03093116 #2024-512606-25-00
Groupe 6
Metastatic NTRK-1/2/3 1 2 3 or more Targeted therapy
Systemic Treatment-Naive
4 recruiting sites
Turning Point Therapeutics, Inc.
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT03093116 #2024-512606-25-00
Groupe 5
Metastatic NTRK-1/2/3 1 2 3 or more Immunotherapy Chemotherapy
Systemic Treatment-Naive Targeted therapy
4 recruiting sites
Turning Point Therapeutics, Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT05875168 #2023-507937-14-00
Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
6 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2 Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT05592626 #2023-505334-10-00
Locally Advanced Metastatic MSI/dMMR 1 2 3 or more
Systemic Treatment-Naive
5 recruiting sites
Marengo Therapeutics, Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06128551
Phase 1b extension de dose et phase 2 cohortes tumeurs solides naïves d'inhibiteurs de KRAS G12C
Locally Advanced Metastatic Metastatic Castration-resistant KRAS G12C 1 2 3 or more
Systemic Treatment-Naive Targeted therapy
7 recruiting sites
Revolution Medicines, Inc.